Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain

BACKGROUND: Fingolimod is an innovative drug with a significant budget impact in the treatment of MS in Spain. The aim of this study was to calculate the direct cost comparison of glatiramer acetate and fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) in Sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchez-de la Rosa, Rainel, Sabater, Eliazar, Casado, Miguel A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651713/
https://www.ncbi.nlm.nih.gov/pubmed/23647721
http://dx.doi.org/10.1186/2191-1991-3-13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651713/
https://www.ncbi.nlm.nih.gov/pubmed/23647721
http://dx.doi.org/10.1186/2191-1991-3-13

Ejemplares similares